An Open Label Phase I Dose Escalation Study Of E7080

Trial Profile

An Open Label Phase I Dose Escalation Study Of E7080

Completed
Phase of Trial: Phase I

Latest Information Update: 04 Apr 2018

At a glance

  • Drugs Lenvatinib (Primary)
  • Indications Lymphoma; Solid tumours
  • Focus Adverse reactions
  • Sponsors Eisai Inc
  • Most Recent Events

    • 19 Apr 2019 Planned End Date changed to 1 Dec 2016.
    • 31 May 2017 Results (n= 452) assessing optimal lenvatinib dose based on population PK and exposure-response analysis using using pooled data from NCT00946153, NCT00121719, NCT00121680, NCT00280397, NCT01268293 and other 8 phase 1 studies in healthy adults, published in the Journal of Clinical Pharmacology
    • 27 Jul 2015 Status changed from active, no longer recruiting to completed according to results published in the Clinical cancer research: an official journal of the American Association for Cancer Research.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top